PHIOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:39):

Stats
本日の出来高	14 003.00
平均出来高	444 770
時価総額	3.12M
EPS	$0 ( 2024-04-03 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kontulis Caitlin	Sell	335	Common stock, $0.0001 par value
2024-02-26	Bitterman Robert J	Buy	2 500	Common stock, $0.0001 par value
2024-02-20	Bitterman Robert J	Sell	1 804	Common stock, $0.0001 par value
2024-02-15	Kontulis Caitlin	Sell	658	Common stock, $0.0001 par value
2024-02-17	Kontulis Caitlin	Sell	523	Common stock, $0.0001 par value

INSIDER POWER
77.17
Last 97 transactions
Buy: 3 139 429 \| Sell: 140 691

ボリューム相関

長: -0.06 (neutral)

短: 0.41 (neutral)

Signal:(46.992) Neutral

Phio Pharmaceuticals Corp 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Phio Pharmaceuticals Corp 相関 - 通貨/商品

-0.31
( neutral )

0.00
( neutral )

0.25
( neutral )

0.30
( neutral )

Phio Pharmaceuticals Corp 財務諸表

Annual	2023
収益:	$0
総利益:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2023
収益:	$0
総利益:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2022
収益:	$0
総利益:	$-193 000 (0.00 %)
EPS:	$-9.95

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-12.43

Financial Reports:

No articles found.

Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.